Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28461077 | 0.70 | BACE1 (0.33) | DRD2BACE1TRPA1 | |
| SCHEMBL882180 | 0.70 | TRPA1 (0.36) | DRD2BACE1TRPA1 | |
| SCHEMBL28807038 | 0.69 | BACE1 (0.33) | DRD2BACE1TRPA1 | |
| SCHEMBL11148071 | 0.68 | GPR84 (0.33) | TRPA1 | |
| SCHEMBL27662416 | 0.68 | BACE1 (0.35) | BACE1TRPA1 | |
| SCHEMBL27930103 | 0.68 | BACE1 (0.35) | BACE1TRPA1 | |
| SCHEMBL10959565 | 0.68 | BACE1 (0.32) | BACE1TRPA1 | |
| SCHEMBL2851413 | 0.67 | BACE1 (0.34) | DRD2BACE1TRPA1 | |
| SCHEMBL27930647 | 0.66 | BACE1 (0.31) | BACE1 | |
| SCHEMBL28206346 | 0.66 | BACE1 (0.31) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910379-B1 | CASPASE INHIBITOR PRODRUGS | VERTEX PHARMA (US) | 2011-10-19 | — | — | EP | claimed |
| US-20110144074-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-16 | — | — | US | claimed |
| US-7879891-B2 | such as (S)-Carbazole-9-carboxylic acid 1-(3a-fluoromethyl-5-oxo-3a,5,6,6a-tetrahydro-furo[3,2-d]oxazol-2-yl)-2-methyl-propyl ester, used for the treatment of diseases related to inflammatory or degenerative conditions | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-02-01 | — | — | US | claimed |
| US-20090215736-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2009-08-27 | — | — | US | claimed |
| US-20080311051-A1 | Caspase-2 Inhibitors And Their Biological Applications | THERAPTOSIS SA (FR) | 2008-12-18 | — | — | US | claimed |
| US-7442790-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2008-10-28 | — | — | US | claimed |
| EP-1923386-A2 | Carbamate caspase inhibitors and uses thereof | Vertex Pharmceuticals Incorporated (US) | 2008-05-21 | — | — | EP | claimed |
| EP-1268425-B1 | CARBAMATE CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2008-01-23 | — | — | EP | claimed |
| US-20080015172-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | claimed |
| US-20070155718-A1 | Caspase inhibitor prodrugs | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-05 | — | — | US | claimed |
| EP-1740614-A2 | CASPASE-2 INHIBITORS AND THEIR BIOLOGICAL APPLICATIONS | Theraptosis S.A. (FR) | 2007-01-10 | — | — | EP | claimed |
| US-7074782-B2 | Carbamate caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-07-11 | — | — | US | claimed |
| WO-2005105829-A2 | CASPASE-2 INHIBITORS AND THEIR BIOLOGICAL APPLICATIONS | THERAPTOSIS S.A. (FR) | 2005-11-10 | — | — | WO | claimed |
| US-20040053920-A1 | Carbamate caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-03-18 | — | — | US | claimed |
| EP-1392289-A2 | CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2004-03-03 | — | — | EP | claimed |
| US-20030092703-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-15 | — | — | US | claimed |
| EP-1268425-A2 | CARBAMATE CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2003-01-02 | — | — | EP | claimed |
| WO-2002094263-A2 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-11-28 | — | — | WO | claimed |
| US-20020028803-A1 | Carbamate caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2002-03-07 | — | — | US | claimed |
| WO-2001072707-A2 | CARBAMATE CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-10-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028803-A1 | Carbamate caspase inhibitors and uses thereof | CASP1, CASP2, CASP3 | DRD2 3404/4885BACE1 50/4885TRPA1 2757/4885 |
| US-20070155718-A1 | Caspase inhibitor prodrugs | CASP1, CASP5, CASP2 | DRD2 3942/4885BACE1 16/4885TRPA1 856/4885 |
| US-20080311051-A1 | Caspase-2 Inhibitors And Their Biological Applications | CASP1, CASP2, CASP9 | DRD2 4035/4885BACE1 22/4885TRPA1 3338/4885 |
| US-20080015172-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP2, CASP9 | DRD2 2110/4885BACE1 56/4885TRPA1 1576/4885 |
| US-20110144074-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP2, CASP9 | DRD2 2124/4885BACE1 54/4885TRPA1 1625/4885 |
| US-20040053920-A1 | Carbamate caspase inhibitors and uses thereof | CASP1, CASP2, CASP3 | DRD2 3404/4885BACE1 50/4885TRPA1 2757/4885 |
| US-20090215736-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP2, CASP9 | DRD2 2124/4885BACE1 54/4885TRPA1 1625/4885 |
| US-20030092703-A1 | Caspase inhibitors and uses thereof | CASP1, CASP2, CASP3 | DRD2 2651/4885BACE1 38/4885TRPA1 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.